| 产品描述: | PKI-166 是一种高效、选择性的,有口服生物活性的 EGFR 酪氨酸激酶抑制剂,IC50 值为 0.7 nM。 |
| 靶点: |
IC50: 0.7 nM (EGFR tyrosine kinase) |
| 体外研究: |
Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine. |
| 体内研究: |
PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth. |
| 参考文献: |
1. Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60(11):2926-35. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.027 ml |
15.134 ml |
30.268 ml |
| 5 mM |
0.605 ml |
3.027 ml |
6.054 ml |
| 10 mM |
0.303 ml |
1.513 ml |
3.027 ml |
| 50 mM |
0.061 ml |
0.303 ml |
0.605 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |